Glasdegib Renal Impairment Study

Phase 1

Completed

• Conditions: Renal Impairment
• Interventions: Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects; Drug: Glasdegib single 100 mg dose in severe renal impairment subjects; Drug: Glasdegib single 100 mg dose in normal healthy subjects

• Registration Number: NCT03596567
• Lead Sponsor: Pfizer

Brief Summary

The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-04-02
• Study Start: 2018-05-17
• Study First Submitted QC: 2018-07-12
• Study First Posted: 2018-07-24
• Primary Completion: 2018-08-28
• Study Completion: 2018-09-19
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-27
• Last Update Posted: 2019-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Healthy female subjects of non child bearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 75 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.

2. Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:

   1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;
   2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
   3. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) are considered to be of childbearing potential.

3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).

4. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.

5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Subjects with Normal Renal Function will Need to Meet the Following Criteria in addition -

1. Normal renal function, eGFR=>90 mL/min, based on the MDRD equation.
2. Matched for age (+/-10years) weight +/-15kg, and gender to subjects in the impaired renal function groups

Subjects with Impaired Renal Function will Need to Meet the Following Criteria in Addition to Those Above

1. Good general health commensurate with the population with chronic kidney disease (renal impairment). 'Health' is defined as no clinically relevant abnormalities (with the exception of hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc. as long as, in the opinion of the investigator, the subject is medically stable, is on a stable drug regimen and can abide by the meals and dietary restrictions outlined in protocol identified by a detailed medical history, full physical examination, measurement of pulse rate and 12 lead ECG as well as clinical laboratory tests (except serum creatinine and eGFR).

2. Stable drug regimen defined as not starting a new drug or changing dosage within seven days or five half lives (whichever is longer) before dosing the study drug.

3. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).

4. Meet one of the following eGFR criteria during the screening period based on the MDRD equation:

   1. Moderate renal impairment: eGFR 30 mL/min and <60 mL/min, or
   2. Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis. For subjects in all groups, the values of serum creatinine obtained at the two screening visits should not be more than 20% different.

Read More

Exclusion Criteria

-Any condition possibly affecting drug absorption (eg, gastrectomy, achlorhydria).

  Renal allograft recipients

  Urinary incontinence without catheterization.

  Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days or 5 half lives (whichever is longer) prior to the dose of glasdegib, until the completion of the last PK sample collection.

  Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days or 5 half lives (whichever is longer) prior to the first dose of trial medication until the completion of the last PK sample collection.

  Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling or unable to use two highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of investigational product and, refrain from sperm donation for the duration of the Study and for at least 90 days after the last dose of investigational product.

  Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
  * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level \> upper limit of normal (ULN);
  * Total bilirubin level 1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is not greater than 0.5 mg/dL.

  For subjects with renal impairment, the following important additional criteria are:

  Subjects with other clinically significant disease that may affect the safety of the subject or that may affect the pharmacokinetics of glasdegib (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc is not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the pharmacokinetics of glasdegib.

  Screening blood pressure =\>180mm Hg (systolic) or\>=110 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial blood pressure (BP) is 180 mm Hg (systolic) or 110 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.

  Screening supine 12 lead ECG demonstrating QTcF \>470 msec or a QRS interval \>120 msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Moderate Renal Impairment Group	Glasdegib single 100 mg dose in moderate renal impairment subjects	Subjects with estimated glomerular filtration rate (eGFR) of =\> 30ml/min and \< 60 ml/min
Severe Renal Impairment Group	Glasdegib single 100 mg dose in severe renal impairment subjects	Subjects with estimated glomerular filtration rate (eGFR) of \< 30 ml/min and not requiring dialysis
Normal Renal Function Group	Glasdegib single 100 mg dose in normal healthy subjects	Subjects with estimated glomerular filtration rate (eGFR) of =\> 90 ml/min

Primary Outcome Measures

Name	Time	Method
Maximum Observed Plasma Concentration (Cmax)	6 days
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]	6 days	AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Secondary Outcome Measures

Name	Time	Method
ECGs	34 days	Heart Rate (beats per minute)
Leukocyte /Urinalysis Lab Panel	34 days	Leukocyte esterase (no units)
pH/Urinalysis Lab Panel	34 days	pH (no unit)
Hemoglobin /Hematology Lab Panel	34 days	Hemoglobin (g/dL)
Potassium/Chemistry Lab Panel	34 days	Potassium (Meq/L)
Urine bilirubin/Urinalysis Lab Panel	34 days	Urine bilirubin (no unit)
AST/Chemistry Lab Panel	34 days	AST (U/L)
Blood Pressure	34 days	Supine Systolic and Diastolic blood pressure (mm of Hg). Reported as Systolic/Diastolic
Pulse Rate	34 days	Pulse Rate will be reported in beats per minute.
Blood/Urinalysis Lab Panel	34 days	Blood (qual) (no units)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).	34 days	concomitant medication and adverse event monitoring.
PR/ECGs	34 days	PR interval (msec),
Hematology Lab Panel	34 days	MCH (pictograms/cell)
BUN /Chemistry Lab Panel	34 days	BUN (mg/dL)
Ketones/Urinalysis Lab Panel	34 days	Ketones (no units)
Nitrites/Urinalysis Lab Panel	34 days	Nitrites (no units)
Albumin/Chemistry Lab Panel	34 days	Albumin (g/dL)
MCHC/Hematology Lab Panel	34 days	MCHC (10\^3/mm\^3)
WBC count/Hematology Lab Panel	34 days	WBC count (10\^3/mm\^3),
Total neutrophils/Hematology Lab Panel	34 days	Total neutrophils (Abs)(10\^3/mm\^3),
Eosinophils/Hematology Lab Panel	34 days	Eosinophils (Abs)(10\^3/mm\^3
Monocytes/Hematology Lab Panel	34 days	Monocytes (Abs)(10\^3/mm\^3)
Basophils/Hematology Lab Panel	34 days	Basophils (Abs) (10\^3/mm\^3)
Lymphocytes/Hematology Lab Panel	34 days	Lymphocytes (Abs) (10\^3/mm\^3)
Total Protein/Chemistry Lab Panel	34 days	Total Protein (g/dL)
ALT/Chemistry Lab Panel	34 days	ALT (U/L)
Alkaline Phosphate/Chemistry Lab Panel	34 days	Alkaline Phosphate (U/L)
Sodium/Chemistry Lab Panel	34 days	Sodium (Meq/L)
Chloride/Chemistry Lab Panel	34 days	Chloride (Meq/L)
Creatinine/Chemistry Lab Panel	34 days	Creatinine (mg/dL),
Glucose/Chemistry Lab Panel	34 days	Glucose (mg/dL),
Calcium/Chemistry Lab Panel	34 days	Calcium (mg/dL),
Total Bilirubin/Chemistry Lab Panel	34 days	Total Bilirubin (mg/dL),
Uric acid/Chemistry Lab Panel	34 days	Uric acid (mg/dL)
Magnesium/Chemistry Lab Panel	34 days	Magnesium (mg/dL)
QTc/ECGs	34 days	QTc interval (msec)
QRS/ECGs	34 days	QRS interval (msec)
Glucose/Urinalysis Lab Panel	34 days	Glucose (qual) (no unit)
Protein/Urinalysis Lab Panel	34 days	Protein (qual) (no unit)
Urobilinogen/Urinalysis Lab Panel	34 days	Urobilinogen (no unit)

Trial Locations

Locations (3)

Prism Clinical Research LLC; 🇺🇸 Saint Paul, Minnesota, United States

University of Miami Division of Clinical Pharmacology; 🇺🇸 Miami, Florida, United States

University of Miami, Sylvester Comprehensive Cancer Center; 🇺🇸 Miami, Florida, United States